Modality
Cell Therapy
MOA
JAK1/2i
Target
Menin
Pathway
Neuroinflam
Gastric CaMGMigraine
Development Pipeline
Preclinical
Apr 2022
→ Jun 2028
PreclinicalCurrent
NCT07703046
1,612 pts·Gastric Ca
2022-04→2028-06·Recruiting
NCT04959441
2,286 pts·Migraine
2022-07→TBD·Terminated
3,898 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-09-216mo awayFast Track· Migraine
2028-06-082.2y awayInterim· Gastric Ca
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Preclinical
Recruit…
Preclinical
Termina…
Catalysts
Fast Track
2026-09-21 · 6mo away
Migraine
Interim
2028-06-08 · 2.2y away
Gastric Ca
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07703046 | Preclinical | Gastric Ca | Recruiting | 1612 | SRI-4 |
| NCT04959441 | Preclinical | Migraine | Terminated | 2286 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 | |
| Cevimavacamten | Denali | NDA/BLA | Menin |